Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 160 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Overweight or Obese Adults Clear all

Conditions: Obesity, Overweight and/or Obesity, Overweight
Interventions: PF-08653944, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 35
States / cities: Canoga Park, California • Escondido, California • Modesto, California + 26 more

Conditions: Obesity, Overweight
Interventions: Eloralintide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 43
States / cities: Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 37 more

Conditions: Overweight or Obesity and Elevated Liver Fat
Interventions: Maridebart cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 23
States / cities: Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more

Conditions: Obesity
Interventions: RGT001-075, Placebo; Drug
Lead sponsor: Regor Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 10
States / cities: Los Angeles, California • Valparaiso, Indiana • Omaha, Nebraska + 7 more

Conditions: Obesity, Overweight
Interventions: Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 25
States / cities: Yuma, Arizona • Lake Forest, California • Long Beach, California + 22 more

Conditions: Sleep Disturbance, Sleep Wake Disorders, Sleep Disorder
Interventions: TranS-C; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Obesity or Overweight
Interventions: AZD5004, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 30
States / cities: Chandler, Arizona • Huntington Park, California • La Mesa, California + 27 more

Conditions: Overweight, Obesity
Interventions: Macupatide, Eloralintide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 40
States / cities: Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 37 more

Conditions: Obesity (BMI Equal to or >30), Immune Function, HDL, Gut Microbiome, Healthy Adult Participants
Interventions: Egg whites, Whole eggs; Other
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 50 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Healthy
Interventions: PF-07081532, Cyclosporine, Itraconazole; Drug · Device
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Interventions: Clazakizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 30
States / cities: Huntsville, Alabama • Tucson, Arizona • Glendora, California + 24 more

Conditions: Dietary Supplement
Interventions: Oligomalt, maltodextrin; Dietary Supplement
Lead sponsor: Société des Produits Nestlé (SPN); Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tustin, California

Conditions: Psoriatic Arthritis, Overweight or Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 53
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more

Conditions: Obesity or Overweight
Interventions: RGT001-075, Placebo Comparator; Drug
Lead sponsor: Regor Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 35
States / cities: Mobile, Alabama • Phoenix, Arizona • Huntington Park, California + 31 more

Conditions: Non-diabetic Overweight or Obese
Interventions: Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week., Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week., Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.; Drug
Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Overweight and Obesity
Interventions: Apitegromab, Placebo, Tirzepatide; Drug
Lead sponsor: Scholar Rock, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Chula Vista, California • Orlando, Florida • Chicago, Illinois + 4 more

Conditions: Overweight, Obesity, Healthy Adults
Interventions: Acetaminophen, Placebo, Weight stigma vignette, Control vignette; Drug · Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Ulcerative Colitis, Obesity or Overweight
Interventions: Mirikizumab, Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: Dothan, Alabama • Anaheim, California • Beverly Hills, California + 30 more

Conditions: Overweight, Obesity
Interventions: Semaglutide Nasal Spray, Placebo, Semaglutide Injection; Drug
Lead sponsor: Shanghai World Leader Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Diabetes Mellitus, Type 2, Food Supply, Poverty, Minority Health, Obesity
Interventions: Fresh organic vegetables; Dietary Supplement
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Diabetes Mellitus, Type 2, Insulin Resistance, Glucose Intolerance, Sleep Disturbance, Overweight or Obesity, Insulin Sensitivity
Interventions: Resistance Exercise Timing; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 50 Years to 74 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Overweight, Obesity
Interventions: PF-07976016, PF-06882961; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Antipsychotic-induced Weight Gain (AIWG)
Interventions: Miricorilant, Placebo; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 27
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 23 more

Conditions: Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
Interventions: Semaglutide, Berobenatide, Tirzepatide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 24
States / cities: Birmingham, Alabama • Canoga Park, California • Los Angeles, California + 20 more

Search by objective public record fields.

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Improving Sleep Health in Adults With Overweight or Obesity

Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Investigation of Egg Intake and the Relationship Between Gut Microbiome, Metabolic, and Immune Profiles

A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

To Evaluate the Post-Prandial Metabolic Effects of Oligomalt in Adults With T2D and in HAO

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects

Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

Pain and Acetaminophen in Women Study

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults

Farming for Life - Health Impact of Organic Vegetable Prescriptions for Adults Living With or at Risk of Type 2 Diabetes

The Acute T-Rex (Timing of Resistance Exercise) Study

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity